A

MKT CAP:$33B

Agilent Technologies, Inc.

Market Cap

$33B

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NYSE

Healthcare·Medical·🇺🇸·NYSE

Stock Price

$115.81-$22.13 (-16.05%)

Apr 24, 2026

Company Details

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; ...

CEO

Padraig McDonnell

IPO Date

Nov 18, 1999

Website

www.agilent.com

Key Metrics TTM

Revenue

$7.1B

+8.1% YoY

Net Income

$1.3B

EPS (Diluted)

$4.53

Free Cash Flow

$993M

Revenue / Share

$24.88

Gross Margin

52.2%

Operating Margin

20.6%

Net Margin

18.3%

FCF Margin

14.1%

P/S

4.6x

P/E

25.4x

Earnings Reports

Q1 2026

Mar 3, 2026

$1.8B+7.0%EPS $1.07

Q4 2025

Dec 19, 2025

$1.9B+9.4%EPS $1.53

Q3 2025

Aug 29, 2025

$1.7B+10.1%EPS $1.18

Q2 2025

May 30, 2025

$1.7B+6.0%EPS $0.75

Q1 2025

Mar 3, 2025

$1.7B+1.4%EPS $1.11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$1.6B	$861M	$360M
Q3 22	$1.7B	$939M	$411M
Q4 22	$1.8B	$1.0B	$471M
Q1 23	$1.8B	$968M	$426M
Q2 23	$1.7B	$924M	$383M
Q3 23	$1.7B	$658M	$133M
Q4 23	$1.7B	$915M	$408M
Q1 24	$1.7B	$908M	$384M
Q2 24	$1.6B	$856M	$363M
Q3 24	$1.6B	$855M	$333M
Q4 24	$1.7B	$916M	$408M
Q1 25	$1.7B	$899M	$376M
Q2 25	$1.7B	$866M	$300M
Q3 25	$1.7B	$914M	$360M
Q4 25	$1.9B	$964M	$443M
Q1 26	$1.8B	$946M	$353M

Valuation

Quarter	P/S	P/E
Q2 22	5.5x	28.2x
Q3 22	5.9x	29.7x
Q4 22	6.0x	32.7x
Q1 23	6.5x	33.9x
Q2 23	5.7x	29.6x
Q3 23	5.1x	31.4x
Q4 23	4.3x	23.8x
Q1 24	5.8x	31.5x
Q2 24	6.2x	32.9x
Q3 24	6.1x	28.2x
Q4 24	5.9x	29.6x
Q1 25	6.5x	33.6x
Q2 25	4.6x	26.1x
Q3 25	5.0x	27.9x
Q4 25	5.9x	31.4x
Q1 26	5.4x	29.7x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	$283M	$219M
Q3 22	$326M	$244M
Q4 22	$448M	$378M
Q1 23	$296M	$220M
Q2 23	$398M	$341M
Q3 23	$562M	$481M
Q4 23	$516M	$432M
Q1 24	$485M	$395M
Q2 24	$333M	$230M
Q3 24	$452M	$360M
Q4 24	$481M	$388M
Q1 25	$431M	$334M
Q2 25	$221M	$107M
Q3 25	$362M	$259M
Q4 25	$545M	$452M
Q1 26	$268M	$175M

Capital Expenditures

Quarter	CapEx
Q2 22	$64M
Q3 22	$82M
Q4 22	$70M
Q1 23	$76M
Q2 23	$57M
Q3 23	$81M
Q4 23	$84M
Q1 24	$90M
Q2 24	$103M
Q3 24	$92M
Q4 24	$93M
Q1 25	$97M
Q2 25	$114M
Q3 25	$103M
Q4 25	$93M
Q1 26	$93M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	+5.4%	+0.8%
Q3 22	+8.3%	+4.6%
Q4 22	+11.4%	+8.9%
Q1 23	+4.9%	+2.5%
Q2 23	+6.8%	+7.0%
Q3 23	-2.7%	+17.8%
Q4 23	-8.7%	-7.1%
Q1 24	-5.6%	-4.2%
Q2 24	-8.4%	-9.3%
Q3 24	-5.6%	-19.1%
Q4 24	+0.8%	+1.0%
Q1 25	+1.4%	+2.4%
Q2 25	+6.0%	+13.1%
Q3 25	+10.1%	+10.7%
Q4 25	+9.4%	+9.7%
Q1 26	+7.0%	+10.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$27M	1.7%
Q3 22	$28M	1.6%
Q4 22	$26M	1.4%
Q1 23	$44M	2.5%
Q2 23	$24M	1.4%
Q3 23	$29M	1.7%
Q4 23	$14M	0.8%
Q1 24	$44M	2.7%
Q2 24	$32M	2.0%
Q3 24	$28M	1.8%
Q4 24	$26M	1.5%
Q1 25	$40M	2.4%
Q2 25	$30M	1.8%
Q3 25	$32M	1.8%
Q4 25	$26M	1.4%
Q1 26	$41M	2.3%

OpEx Breakdown

Quarter	R&D	SG&A
Q2 22	$115M	$386M
Q3 22	$116M	$412M
Q4 22	$119M	$422M
Q1 23	$123M	$419M
Q2 23	$126M	$415M
Q3 23	$118M	$407M
Q4 23	$114M	$393M
Q1 24	$128M	$396M
Q2 24	$113M	$380M
Q3 24	$127M	$395M
Q4 24	$111M	$397M
Q1 25	$113M	$410M
Q2 25	$112M	$454M
Q3 25	$111M	$417M
Q4 25	$119M	$428M
Q1 26	$117M	$476M

Revenue Segments

Quarter	Agilent CrossLab	Diagnostics and Genomics	Life Sciences and Applied Markets	Applied Markets
Q2 22	$353M	$358M	$896M	—
Q3 22	$359M	$340M	$1.0B	—
Q4 22	$381M	$352M	$1.1B	—
Q1 23	$381M	$342M	$1.0B	—
Q2 23	$387M	$362M	$968M	—
Q3 23	$396M	$349M	$927M	—
Q4 23	$404M	$356M	$928M	—
Q1 24	$405M	$407M	$846M	—
Q2 24	$402M	$417M	$754M	—
Q3 24	$411M	$385M	$782M	—
Q4 24	$426M	$442M	$833M	—
Q1 25	$696M	—	$647M	$338M
Q2 25	$713M	—	$654M	$301M
Q3 25	$744M	—	$670M	$324M
Q4 25	$755M	—	$755M	$351M
Q1 26	$758M	—	$679M	$361M

Revenue by Geography

Quarter	Americas	Asia Pacific	Europe
Q2 22	$659M	$525M	$423M
Q3 22	$671M	$640M	$407M
Q4 22	$715M	$716M	$418M
Q1 23	$687M	$613M	$456M
Q2 23	$676M	$608M	$433M
Q3 23	$667M	$573M	$432M
Q4 23	$702M	$553M	$433M
Q1 24	$630M	$570M	$458M
Q2 24	$637M	$510M	$426M
Q3 24	$626M	$520M	$432M
Q4 24	$680M	$567M	$454M
Q1 25	$669M	$549M	$463M
Q2 25	$678M	$548M	$442M
Q3 25	$683M	$563M	$492M
Q4 25	$776M	$559M	$526M
Q1 26	$678M	$602M	$518M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$1.2B	$21M	$1.2B
Q3 22	$1.1B	$6M	$1.1B
Q4 22	$1.1B	$0	$1.1B
Q1 23	$1.3B	$0	$1.3B
Q2 23	$1.2B	$0	$1.2B
Q3 23	$1.3B	$0	$1.3B
Q4 23	$1.6B	$0	$1.6B
Q1 24	$1.7B	$0	$1.7B
Q2 24	$1.7B	$0	$1.7B
Q3 24	$1.8B	$0	$1.8B
Q4 24	$1.3B	$0	$1.3B
Q1 25	$1.5B	$0	$1.5B
Q2 25	$1.5B	$0	$1.5B
Q3 25	$1.5B	$0	$1.5B
Q4 25	$1.8B	$0	$1.8B
Q1 26	$1.8B	$0	$1.8B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	301M	-0.7%	-2.0%
Q3 22	299M	-0.7%	-2.3%
Q4 22	298M	-0.3%	-2.3%
Q1 23	297M	-0.3%	-2.0%
Q2 23	297M	0.0%	-1.3%
Q3 23	295M	-0.7%	-1.3%
Q4 23	293M	-0.7%	-1.7%
Q1 24	294M	+0.3%	-1.0%
Q2 24	293M	-0.3%	-1.3%
Q3 24	291M	-0.7%	-1.4%
Q4 24	291M	0.0%	-0.7%
Q1 25	287M	-1.4%	-2.4%
Q2 25	285M	-0.7%	-2.7%
Q3 25	285M	0.0%	-2.1%
Q4 25	284M	-0.4%	-2.4%
Q1 26	284M	0.0%	-1.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$94.5K	17K
Q3 22	$101.1K	17K
Q4 22	$102.2K	18K
Q1 23	$97.0K	18K
Q2 23	$94.9K	18K
Q3 23	$92.4K	18K
Q4 23	$93.3K	18K
Q1 24	$91.6K	18K
Q2 24	$86.9K	18K
Q3 24	$87.2K	18K
Q4 24	$95.0K	18K
Q1 25	$93.9K	18K
Q2 25	$93.2K	18K
Q3 25	$97.1K	18K
Q4 25	$102.8K	18K
Q1 26	$99.3K	18K

Revenue / Employee